Literature DB >> 6144127

Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

L T Kucharski, P Alexander, L Tune, J Coyle.   

Abstract

Twenty-two acutely psychotic patients were rigorously assessed for psychopathology at baseline and after 14 days of neuroleptic treatment. The neuroleptic radioreceptor assay (NRRA) was used to determine serum neuroleptic concentrations. Serum neuroleptic concentration was significantly, nonlinearly related to changes in BPRS Total Score, and BPRS Factor Scores for Thought Disturbance and Anxiety-Depression. Clinical improvement was associated with intermediate (11-50, 51-126 ng/ml haloperidol equivalents) while poor clinical outcome was related to both low (less than or equal to 10 ng/ml) or high (greater than 125 ng/ml) serum levels. The results are discussed in terms of a possible "therapeutic window" for the neuroleptics and the implications this might have for clinical practice.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144127     DOI: 10.1007/bf00427772

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.

Authors:  I Creese; S H Snyder
Journal:  Nature       Date:  1977-11-10       Impact factor: 49.962

2.  Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios.

Authors:  G Sakalis; T L Chan; G Sathananthan; N Schooler; S Goldberg; S Gershon
Journal:  Commun Psychopharmacol       Date:  1977

3.  The possible role of metabolites in therapeutic response to chlorpromazine treatment.

Authors:  G Sakalis; T L Chan; S Gershon; S Park
Journal:  Psychopharmacologia       Date:  1973-09-28

4.  Neuroleptic blood levels and therapeutic effect.

Authors:  B M Cohen; J F Lipinski; H G Pope; P Q Harris; R I Altesman
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

5.  Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.

Authors:  R Rimón; I Averbuch; P Rozick; L Fijman-Danilovich; T Kara; H Dasberg; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  High serum neuroleptic levels in tardive dyskinesia?

Authors:  D V Jeste; J E Rosenblatt; R L Wagner; R J Wyatt
Journal:  N Engl J Med       Date:  1979-11-22       Impact factor: 91.245

7.  Measurement of serum neuroleptic concentration by radioreceptor assay: concurrent assessment of clinical psychosis ratings.

Authors:  J E Rosenblatt; C B Pert; J Colison; D P van Kammen; R Scott; W E Bunney
Journal:  Commun Psychopharmacol       Date:  1979

8.  Relationship of serum haloperidol levels to clinical response in schizophrenic patients.

Authors:  J R Magliozzi; L E Hollister; K V Arnold; G M Earle
Journal:  Am J Psychiatry       Date:  1981-03       Impact factor: 18.112

9.  Tardive dyskinesia and hospital discharge.

Authors:  L T Kucharski; J M Smith; D D Dunn
Journal:  J Nerv Ment Dis       Date:  1980-04       Impact factor: 2.254

10.  Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.

Authors:  L Rivera-Calimlim; H Nasrallah; J Strauss; L Lasagna
Journal:  Am J Psychiatry       Date:  1976-06       Impact factor: 18.112

View more
  4 in total

Review 1.  Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.

Authors:  M R Caligiuri; D V Jeste; J P Lacro
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 2.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

3.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

4.  Haloperidol plasma levels and clinical response in paranoid schizophrenics.

Authors:  P Linkowski; P Hubain; R von Frenckell; J Mendlewicz
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.